Please login to the form below

Not currently logged in


This page shows the latest Symkevi news and features for those working in and with pharma, biotech and healthcare.

Vertex faces rejection of its CF medicines in Scotland

Vertex faces rejection of its CF medicines in Scotland

Another rejection over cost-effectiveness. The Scottish Medicines Consortium (SMC) has not recommended Vertex’s cystic fibrosis drugs Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) for routine NHS use in Scotland. .

Latest news

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    of CF patients and now Symkevi (ivacaftor and tezacaftor). This is effective for people who have two copies of the F508del mutation plus those with one of 14 other mutations.

  • The Orkambi row explained The Orkambi row explained

    It refuses to file Symkevi with NICE, stating that it will only submit its data if NICE updates its appraisal process. ... December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... The hope is that both sides can come to a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....